These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 20435379)

  • 1. [How long should combined therapy with biological and immunomodulatory agents be maintained in inflammatory bowel disease?].
    Domènech E; López San Román A; Garcia-Planella E
    Gastroenterol Hepatol; 2010; 33(6):471-2; author reply 472-3. PubMed ID: 20435379
    [No Abstract]   [Full Text] [Related]  

  • 2. New and emerging biologics in the treatment of inflammatory bowel disease: quo vadis?
    Danese S; Angelucci E
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S217-27. PubMed ID: 20117345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2009 Jul; 25(4):323-8. PubMed ID: 19417645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases.
    Ghosh N; Chaki R; Mandal V; Lin GD; Mandal SC
    Int Rev Immunol; 2010; 29(1):4-37. PubMed ID: 20100080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Biologicals first-line in chronic inflammatory bowel disease? No].
    Herrlinger K; Stange EF
    Dtsch Med Wochenschr; 2011 Sep; 136(36):1789. PubMed ID: 21882135
    [No Abstract]   [Full Text] [Related]  

  • 6. Inflammatory bowel disease: short- and long-term treatments.
    Bickston SJ; Cominelli F
    Adv Intern Med; 1998; 43():143-74. PubMed ID: 9506181
    [No Abstract]   [Full Text] [Related]  

  • 7. [Biologic therapy for inflammatory bowel diseases].
    Bosques Padilla F
    Rev Gastroenterol Mex; 2006 Aug; 71 Suppl 1():91-4. PubMed ID: 17037786
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety issues with biological therapies for inflammatory bowel disease.
    Van Assche G; Vermeire S; Rutgeerts P
    Curr Opin Gastroenterol; 2006 Jul; 22(4):370-6. PubMed ID: 16760752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
    Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
    Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are patients with inflammatory bowel disease receiving optimal care?
    Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
    Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of combining immunosuppressive and biological treatments in inflammatory bowel disease.
    Roblin X; Phelip JM
    Arch Intern Med; 2008 Mar; 168(6):667; author reply 667-8. PubMed ID: 18362263
    [No Abstract]   [Full Text] [Related]  

  • 12. [Current medical treatment of inflammatory bowel disease].
    Bosques-Padilla F
    Rev Gastroenterol Mex; 2007 Nov; 72 Suppl 2():92-101. PubMed ID: 18277494
    [No Abstract]   [Full Text] [Related]  

  • 13. New Zealand Society of Gastroenterology statement on the use of biological therapy in inflammatory bowel disease.
    Schultz M; Gearry R; Walmsley R; Day AS; Fraser A; Wyeth J; Barclay M; Clover G; Whiteside C
    N Z Med J; 2010 May; 123(1314):134-44. PubMed ID: 20590012
    [No Abstract]   [Full Text] [Related]  

  • 14. Timing infliximab therapy in pediatric Crohn's disease.
    Kirschner BS; Huo D
    Gastroenterology; 2007 Mar; 132(3):1167-70. PubMed ID: 17383435
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prevention of post-surgical recurrence of Crohn's disease. A perspective].
    Paviotti A; Terrosu G; Avellini C; Girometti R; Sorrentino D
    Recenti Prog Med; 2009 May; 100(5):233-8. PubMed ID: 19772213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The great debate: stopping immunomodulators and biologics in Crohn's disease patients in remission.
    Hashash JG; Regueiro MD
    Expert Rev Gastroenterol Hepatol; 2013 Aug; 7(6):501-3. PubMed ID: 23984997
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of chronic inflammatory bowel diseases. TNF-alpha blocker in Crohn disease: earlier use is rewarding].
    MMW Fortschr Med; 2008 Dec; 150(51-52):54-5. PubMed ID: 19156959
    [No Abstract]   [Full Text] [Related]  

  • 18. Management of inflammatory bowel disease: past, present and future.
    Keyashian K; Annunziata ML; Sakuraba A; Hanauer S
    Expert Rev Clin Immunol; 2012 May; 8(4):303-5. PubMed ID: 22607175
    [No Abstract]   [Full Text] [Related]  

  • 19. [Biological therapy of inflammatory bowel disease].
    Lazebnik LB; Parfenov AI; Kniazev OV; Konopliannikov AG; Sagynbaeva VE; Iakovleva MV; Astrelina TA; Ruchkina IN; Shcherbakov PL; Trubitsyna IE; Tsaregorodtseva TM; Gudkova RB; Rogozina VA; Chikunova BZ; Khomeriki SG; Mikhaĭlova ZF
    Eksp Klin Gastroenterol; 2011; (2):7-14. PubMed ID: 21560638
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.